Search Results 161-170 of 17236 for hba1c

  1. A Study To Evaluate How Semaglutide Works Compared To Placebo In People With Type 2 Diabetes And Chronic Kidney Disease - Mayo Clinic

    Male or female, age above or equal to 18 years at the time of signing informed consent. · Diagnosed with type 2 diabetes mellitus. · HbA1c less than or equal to ...

  2. A Phase 2b, Study Of Linsitinib In Subjects With Active, Moderate To Severe Thyroid Eye Disease (TED) - Mayo Clinic

    Diabetic subjects must have HbA1c < 9.0%. Type 2 diabetic subjects who are not on insulin, must not be prescribed insulin within 60 days prior to screening ...

  3. Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF - Mayo Clinic

    Uncontrolled diabetes (HBA1c >10%) or history of recurrent ketoacidosis. Wilson's disease. History of malignant hyperthermia. Uncontrolled psychiatric ...

  4. https://www.mayoclinic.org/arabic_patient_consumer_video.xml

  5. Efficacy And Safety Of Treatment With Alpelisib Plus Endocrine Therapy In Patients With HR+, HER2-negative ABC, With PIK3CA Mutations, Whose Disease Has Progressed On Or After CDK 4/6 Treatment With An Aromatase Inhibitor (AI) Or Fulvestrant - Mayo Clinic

    ... (HbA1c) ≤ 6.4% (both criteria have to be met). *For patients with FPG ≥ 100 mg/dL and/or HbA1c ≥ 5.7% (i.e., threshold for pre-diabetes) at screening ...

  6. Phase 3 Study To Evaluate The Efficacy And Safety Of Elafibranor Versus Placebo In Patients With Nonalcoholic Steatohepatitis (NASH) - Mayo Clinic

    Patients with decompensated diabetes (HbA1c>9%). Patients with a history of clinically significant acute cardiac event within 6 months prior to screening ...

  7. Study Of Ravulizumab In Immunoglobulin A Nephropathy (IgAN) - Mayo Clinic

    * Uncontrolled diabetes mellitus with glycosylated hemoglobin (HbA1c) > 8.5%. * Henoch-Schonlein purpura (IgAV) requiring systemic immunosuppressive therapy ...

  8. Pemafibrate To Reduce Cardiovascular OutcoMes By Reducing Triglycerides IN PatiENts With DiabeTes (PROMINENT) - Mayo Clinic

    ... HbA1c (≥ 6.5% [48 mmol/mol]), elevated plasma glucose (fasting ≥ 126 mg/dL [7.0 mmol/L], 2-hour ≥ 200 mg/dL [11.1 mmol/L] during oral glucose tolerance ...

  9. Study Of BIIB092 In Participants With Progressive Supranuclear Palsy - Mayo Clinic

    Hemoglobin A1C (HbA1C) > 8%, confirmed by repeat. Allergies and Adverse Drug Reaction. History of allergy, hypersensitivity, or serious adverse reaction to ...

  10. A Study To Evaluate The Effectiveness And Safety Of TAK-906 In Adult Participants With Symptomatic Idiopathic Or Diabetic Gastroparesis - Mayo Clinic

    A subject with diabetes mellitus must have HbA1c ≤11% before the randomization visit. During Screening Period. The subject has shown compliance with the ...